TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10188113
Drug: Oral lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral lorazepam 0.025 mg/kg
Study: 8540943
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose infusion at 180 mL/h (9 g/h)
Study: 31710398
Drug: Topical alprostadil
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical alprostadil
Study: 12479119
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection
Study: 30206130
Drug: High-Flow Nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Flow Nasal Cannula (HFNC) at 2 L/kg/min
Study: 30206130
Drug: High-Flow Nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Flow Nasal Cannula (HFNC) at 1 L/kg/min
Study: 23980043
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding with enteral nutrition
Study: 21366964
Drug: MSM+EDTA lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSM+EDTA lotion
Study: 17684963
Drug: Epoetin and
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin and iron preparations
Study: 17684963
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of epoetin and parenteral iron preparations
Study: 15173493
Drug: Nedocromil 16
Normalized name: NEDOCROMIL
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil 16 mg/day
Study: 6242073
Drug: Oral tetracyclines
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tetracyclines 500 mg b.i.d.
Study: 29617739
Drug: RBX2660 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBX2660 (2 doses)
Study: 29617739
Drug: RBX2660 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBX2660 (1 dose) followed by Placebo (1 dose)
Study: 29617739
Drug: RBX2660 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBX2660 (1 dose)
Study: 27046798
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose antithrombin (3000 IU/daily)
Study: 22185431
Drug: 1.62% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.62% testosterone gel (81 mg testosterone) applied once daily for 7 days with washing at 2 hours post-dose
Study: 22185431
Drug: 1.62% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.62% testosterone gel (81 mg testosterone) applied once daily for 7 days with washing at 6 hours post-dose
Study: 22185431
Drug: 1.62% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.62% testosterone gel (81 mg testosterone) applied once daily for 7 days with washing at 10 hours post-dose
Study: 22185431
Drug: 1.62% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.62% testosterone gel (81 mg testosterone) applied once daily for 7 days with no washing
Study: 24527596
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug therapy
Study: 17912169
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow stem cell therapy (BM-derived cells injected into infarcted hearts)
Study: 19239460
Drug: Dutasteride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride (0.5 mg)
Study: 8780347
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg gastric-delivery-system (GDS) iron supplement
Study: 8780347
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg conventional (Con) iron supplement
Study: 28856398
Drug: Current use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current use of SSRIs (last tablet noted ≤ 7 days before diagnosis)
Study: 28856398
Drug: Late use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late use of SSRIs (last tablet noted ≥ 8 days before diagnosis)
Study: 21175345
Drug: Older ovariectomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older ovariectomized rats receiving exogenous estrogen treatment (17-β-estradiol)
Study: 21175345
Drug: Modulation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modulation of estrogen status in 1-year-old animals (e.g., ovariectomy or continuous exposure to estrogen)
Study: 11392363
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) at half dose
Study: 8276557
Drug: Enoxaparin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (20 mg daily, starting 2 hours before surgery)
Study: 8276557
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin (2 doses of 0.2 ml daily, starting 2 hours before surgery)
Study: 3524744
Drug: Intramuscular chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular chloroquine diphosphate, 2.5 mg base/kg at 0, 1, 12, 13, 24, and 25 hours
Study: 3524744
Drug: Subcutaneous chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous chloroquine diphosphate, 5 mg base/kg at 0, 12, and 24 hours
Study: 3524744
Drug: Intramuscular chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular chloroquine diphosphate
Study: 3524744
Drug: Subcutaneous chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous chloroquine diphosphate
Study: 28618198
Drug: IV paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV paracetamol pre-emptive analgesia (15 mg/kg before treatment)
Study: 28618198
Drug: IV paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV paracetamol preventive analgesia (15 mg/kg at the end of treatment)
Study: 28618198
Drug: IV paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV paracetamol pre-emptive analgesia
Study: 25306220
Drug: Individualised best
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised best practice ergonomic intervention plus 3×20 minute weekly, progressive neck/shoulder girdle exercise group sessions for 12 weeks.
Study: 25306220
Drug: Individualised best
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised best practice ergonomic intervention plus 1‐hour weekly health information sessions for 12 weeks.
Study: 30943497
Drug: Bromazepam 3
Normalized name: bromazepam 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam 3 mg
Study: 7713242
Drug: Methazolamide 50
Normalized name: methazolamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methazolamide 50 mg q.i.d. for 2 weeks
Study: 28662531
Drug: Maximal leg
Normalized name: Crab leg
DrugBank: Crab leg (DB11011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal leg strength program (80-95% of 1-RM, 1-3 repetitions, 3-6 sets, 3-4 min rest between sets) performed twice a week for 10 weeks.
Study: 25366615
Drug: Cilostazol 200
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 200 mg/day with enteral nutrition (EN) and parenteral nutrition (PN)
Study: 21431373
Drug: Single high‐dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high‐dosage extracorporeal shockwave therapy (0.3 mJ/mm(2))
Study: 21431373
Drug: Two sessions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two sessions of low‐dosage extracorporeal shockwave therapy (0.2 mJ/mm(2))
Study: 16691091
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (MT; mainly spinal mobilization)
Study: 16691091
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT; mainly exercise therapy)
Study: 16691091
Drug: Continued care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued care by the general practitioner (GP; analgesics, counseling and education)
Study: 1405268
Drug: Intravenous large
Normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous large dose streptokinase
Study: 3894494
Drug: Cimetidine (Tagamet)
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine (Tagamet) 300 mg q.i.d.
Study: 3894494
Drug: Mylanta II
Normalized name: Mylanta II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mylanta II 10 ml q.i.d.
Study: 28165762
Drug: Guanfacine extended-release
Normalized name: Guanfacine Extended-Release Tablets
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guanfacine extended-release (GXR) 1-6 mg daily
Study: 18419443
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B inhalation (twice a week until neutrophil counts >300 cells/mm3)
Study: 18419443
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B inhalation (on-treatment analysis)
Study: 18419443
Drug: Placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation (on-treatment analysis)
Study: 16850791
Drug: Restoration treatment
Normalized name: CALCIUM 0.55 ORAL TABLET [Restoration Treatment]
DrugBank: Calcium (DB01373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restoration treatment
Study: 8792943
Drug: Prescription medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription medications (self-reported use)
Study: 8792943
Drug: Gender comparison
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gender comparison in medication use
Study: 8792943
Drug: Factors associated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factors associated with greater medication use
Study: 8792943
Drug: Age-related medication
Normalized name: casein, Lactococcus lactis cultured, aged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age-related medication use
Study: 8792943
Drug: Gender-related medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gender-related medication use
Study: 1634705
Drug: Milacemide 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milacemide 1200 mg/day for 1 month
Study: 2164477
Drug: Metoprolol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (beta 1-selective blocker)
Study: 6326999
Drug: Combined radiotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined radiotherapy and chemotherapy
Study: 29441742
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) combined with low-dose corticosteroids
Study: 29441742
Drug: Cyclosporine (CsA)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CsA) combined with low-dose corticosteroids
Study: 25765590
Drug: Enoxaparin 1
Normalized name: ENOXAPARIN 100MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1 mg/kg (maximum 100 mg) subcutaneously every 12 hours for 30 days
Study: 25765590
Drug: Traditional anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional anticoagulation (intravenous heparin followed by oral warfarin for 3 months)
Study: 21183917
Drug: Omaron (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omaron (25 mg of cinnarizine and 400 mg of piracetam), 1 tablet 3 times a day for 12 weeks
Study: 16688202
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (HFNC) at 3, 4, and 5 l/min
Study: 12568837
Drug: L‐carnitine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐carnitine therapy 2 g/day
Study: 9816321
Drug: UFT at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT at a dose of 400 mg/m2/day administered as three divided doses (every 8 h)
Study: 9816321
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dosing of UFT
Study: 9816321
Drug: UFT at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT at a dose of 300 mg/m2/day
Study: 9816321
Drug: UFT at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT at a dose of 400 mg/m2/day
Study: 1466210
Drug: Brotizolam 0.25-0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brotizolam 0.25-0.50 mg sublingually
Study: 1466210
Drug: Diazepam 5-10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5-10 mg orally
Study: 6717216
Drug: Moxalactam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxalactam (30 mg/kg) for 3 doses postoperatively
Study: 6717216
Drug: Moxalactam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxalactam (30 mg/kg) for 6 doses postoperatively
Study: 25825138
Drug: Compressive cryotherapy
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compressive cryotherapy (CC)
Study: 23370528
Drug: L-Name (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Name (20 μg min⁻¹ kg⁻¹) during OGTT
Study: 23370528
Drug: L-Name (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Name (at rates of 2.5, 5, 10 and 20 μg min⁻¹ kg⁻¹) during hyperglycaemic clamps
Study: 22214253
Drug: Eucommia extract
Normalized name: Eucommia ulmoides bark extract
DrugBank: Eucommia ulmoides bark (DB14259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eucommia extract 500 mg three times daily for eight weeks
Study: 22214253
Drug: Eucommia extract
Normalized name: Eucommia ulmoides bark extract
DrugBank: Eucommia ulmoides bark (DB14259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eucommia extract 1 g three times daily for two weeks
Study: 19597364
Drug: Psychodynamic Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic Group Therapy (PGT) plus clonazepam
Study: 11669470
Drug: Remifentanil (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (target plasma concentrations: 0, 1.2, 1.8, 2.4, 3, 3.6, 4.8, and 6 ng/ml)
Study: 9721772
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of conjugated equine estrogen (n = 20)
Study: 9721772
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of simvastatin (n = 18)
Study: 9721772
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (n = 17)
Study: 958162
Drug: Porfiromycin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porfiromycin (75 mg/M2 every 6-8 weeks as a single bolus i.v. injection)
Study: 958162
Drug: Mitomycin-C (22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin-C (22.5 mg/M2 every 6-8 weeks as a single bolus i.v. injection)
Study: 21168536
Drug: teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: teriparatide 20 μg/day
Study: 23647283
Drug: Self-help treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-help treatment administered in a group
Study: 9411464
Drug: Longer treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer treatment duration
Study: 18154644
Drug: Sustained-release oral
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release oral morphine (SRM)
Study: 9247842
Drug: Oral tolterodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tolterodine 3.2 mg
Study: 9247842
Drug: Oral tolterodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tolterodine 6.4 mg
Study: 9247842
Drug: Oral tolterodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tolterodine 12.8 mg
Study: 9247842
Drug: Oral tolterodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tolterodine (14C) 5 mg
Study: 7682488
Drug: L-carnitine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (6 g daily)
Study: 6180562
Drug: Propafenone (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (900 mg daily)
Study: 7682488
Drug: Propafenone (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (900 mg daily) plus L-carnitine (6 g daily)
Study: 3117401
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of 20‐30 mg adriamycin for 4 weeks or 2 years
Study: 3117401
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of 20 mg mitomycin C for 4 weeks or 2 years
Study: 31870492
Drug: Intracoronary tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary tenecteplase (TNK) 4 mg
Study: 24865871
Drug: Parent-focused treatment
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-focused treatment (PFT)
Study: 29480503
Drug: Community-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based treatment as usual (TAU)
Study: 19787711
Drug: Non-surgical therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical therapy (continence pessary, pelvic floor muscle training or combined)
Study: 14581122
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment with gabapentin
Study: 10809260
Drug: Dopamine (4-hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine (4-hr infusions at doses of placebo, 3, 7, and 12 microg/kg/min)
Study: 10809260
Drug: Dobutamine (4-hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine (4-hr infusions at doses of placebo, 3, 7, and 12 microg/kg/min)
Study: 7768249
Drug: Loxiglumide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (10 mg.kg‐1.h‐1)
Study: 9071422
Drug: Azithromycin 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 2.0 g orally
Study: 6303490
Drug: Ceftriaxone 250
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 250 mg intramuscularly
Study: 25600977
Drug: Low C-form
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low C-form (10 mg lenvatinib, <4% crystalline)
Study: 25600977
Drug: High C-form
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High C-form (10 mg lenvatinib, 38% crystalline)
Study: 25600977
Drug: Reference C-form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference C-form (10 mg lenvatinib, 15% crystalline)
Study: 10874974
Drug: Intraarterial chemoperfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial chemoperfusion (CP) with mitoxantrone (820 mg/m2 for 1-2 hours)
Study: 10874974
Drug: Intraarterial embolization
Normalized name: HOSE ANTI-EMBOLISM CALF LEN LARGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial embolization therapy (ET) using Histoacryl or Ethibloc
Study: 7594333
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg lansoprazole by slow intravenous injection twice daily for 3 days (six injections)
Study: 7594333
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg lansoprazole by slow intravenous injection twice daily for 3 days (six injections)
Study: 2102066
Drug: kanamycin sulphate
Normalized name: Kanamycin sulphate
DrugBank: Kanamycin (DB01172)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: kanamycin sulphate alternated to polydeoxyribonucleotide vaginal suppositories
Study: 396654
Drug: Pirenzepine (PRZ)
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (PRZ) 75 mg/day for 10 days followed by 50 mg/day for 20 days
Study: 396654
Drug: Carbenoxolone (CB)
Normalized name: carbenoxolone
DrugBank: Carbenoxolone (DB02329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone (CB) 300 mg/day followed by 200 mg/day
Study: 28600039
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of misoprostol vaginally every 12 hours after an 800-μg vaginal loading dose
Study: 28600039
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of misoprostol sublingually every 12 hours after an 800-μg vaginal loading dose
Study: 28600039
Drug: Sequential sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential sublingual misoprostol after a vaginal loading dose
Study: 28600039
Drug: Sequential sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential sublingual misoprostol regimen
Study: 31268872
Drug: Allopurinol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (600 mg/day)
Study: 19473601
Drug: HX575 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: HX575 (100 IU/kg body weight, subcutaneous, three-times-weekly for 4 weeks)
Study: 19473601
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta (100 IU/kg body weight, subcutaneous, three-times-weekly for 4 weeks)
Study: 17978603
Drug: Renin‐angiotensin system‐blocking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin‐angiotensin system‐blocking agents
Study: 17978603
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of other agents if needed to meet blood pressure goal
Study: 11124759
Drug: Modified Sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Sham Feeding (MSF) with 38 g fat
Study: 11124759
Drug: Control: Lunch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: Lunch with 38 g fat
Study: 2691568
Drug: Intramuscular recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular recombinant interferon alpha‐2a (r‐IFN) at doses of 4.5 megaunits thrice weekly for 4 months
Study: 31204839
Drug: Face-to-face (FTF)
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face (FTF) treatment, 1-week treatment
Study: 31204839
Drug: FTF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTF treatment